Uncategorized

#ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study

Published

on

Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit could translate to Western patients.

Patients who …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version